César Serrano

4.0k total citations · 1 hit paper
103 papers, 2.1k citations indexed

About

César Serrano is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Surgery. According to data from OpenAlex, César Serrano has authored 103 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Pulmonary and Respiratory Medicine, 74 papers in Gastroenterology and 24 papers in Surgery. Recurrent topics in César Serrano's work include Gastrointestinal Tumor Research and Treatment (74 papers), Sarcoma Diagnosis and Treatment (44 papers) and Gastric Cancer Management and Outcomes (40 papers). César Serrano is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (74 papers), Sarcoma Diagnosis and Treatment (44 papers) and Gastric Cancer Management and Outcomes (40 papers). César Serrano collaborates with scholars based in Spain, United States and United Kingdom. César Serrano's co-authors include Suzanne George, Sebastian Bauer, Michael C. Heinrich, Martee L. Hensley, Isabelle Ray‐Coquard, Claudia Valverde, Robin L. Jones, Patrick Schöffski, Margaret von Mehren and Jonathan A. Fletcher and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

César Serrano

91 papers receiving 2.1k citations

Hit Papers

Ripretinib in patients with advanced gastrointestinal str... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
    2020 251 citations Jean‐Yves Blay, César Serrano et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
César Serrano Spain 24 1.3k 1.1k 585 459 343 103 2.1k
Gina Z. D’Amato United States 16 1.0k 0.8× 538 0.5× 280 0.5× 447 1.0× 193 0.6× 75 1.3k
Daniel A. Rushing United States 20 771 0.6× 286 0.3× 283 0.5× 564 1.2× 126 0.4× 42 1.5k
Javier Martínez‐Trufero Spain 20 1.1k 0.9× 175 0.2× 533 0.9× 976 2.1× 110 0.3× 124 2.0k
B. Bui France 24 1.5k 1.2× 356 0.3× 451 0.8× 826 1.8× 242 0.7× 63 2.0k
J. Buesa Spain 26 2.9k 2.3× 561 0.5× 687 1.2× 2.1k 4.5× 223 0.7× 61 3.6k
Claudia Valverde Spain 20 688 0.5× 283 0.3× 341 0.6× 391 0.9× 115 0.3× 84 1.1k
Rodrigo Ruiz‐Soto United States 16 544 0.4× 526 0.5× 242 0.4× 438 1.0× 191 0.6× 61 1.3k
Arthur P. Staddon United States 29 2.4k 1.9× 167 0.1× 318 0.5× 1.4k 3.1× 230 0.7× 67 3.5k
Darrel P. Cohen United States 13 788 0.6× 621 0.6× 261 0.4× 280 0.6× 210 0.6× 31 1.2k
Agnès Neuville France 27 1.2k 1.0× 100 0.1× 307 0.5× 704 1.5× 154 0.4× 56 2.0k

Countries citing papers authored by César Serrano

Since Specialization
Citations

This map shows the geographic impact of César Serrano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by César Serrano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites César Serrano more than expected).

Fields of papers citing papers by César Serrano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by César Serrano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by César Serrano. The network helps show where César Serrano may publish in the future.

Co-authorship network of co-authors of César Serrano

This figure shows the co-authorship network connecting the top 25 collaborators of César Serrano. A scholar is included among the top collaborators of César Serrano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with César Serrano. César Serrano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elliott, Andrew, César Serrano, Margaret von Mehren, et al.. (2025). DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas. Cancers. 17(12). 1962–1962. 1 indexed citations
2.
Guerrero, Mario, et al.. (2025). Preclinical study of microphthalmia-associated transcription factor inhibitor ML329 in gastrointestinal stromal tumor growth. PubMed. 33(2). 200983–200983. 1 indexed citations
3.
Matito, Judit, María Quindós, Claudia Valverde, et al.. (2025). Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway. JCO Precision Oncology. 9(9). e2400497–e2400497.
4.
Heinrich, Michael C., Jian Li, Robin L. Jones, et al.. (2023). Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.. Journal of Clinical Oncology. 41(16_suppl). 11523–11523. 1 indexed citations
5.
Serrano, César, Javier Martín‐Broto, José Manuel Asencio, et al.. (2023). 2023 GEIS Guidelines for gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology. 15. 2637124–2637124. 38 indexed citations
6.
Deshayes, Sébastien, et al.. (2023). LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib. International Journal of Molecular Sciences. 24(8). 7138–7138. 7 indexed citations
7.
Xu, Liangliang, Weili Yang, César Serrano, et al.. (2023). Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1869(5). 166690–166690. 7 indexed citations
8.
Heinrich, Michael C., Robin L. Jones, Suzanne George, et al.. (2023). Clinical Benefit of Avapritinib in KIT- Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies. Clinical Cancer Research. 30(4). 719–728. 4 indexed citations
9.
Yeste, José, María Alejandra Ortega, Anna Lena Lopez, et al.. (2022). Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy. npj Precision Oncology. 6(1). 90–90. 7 indexed citations
10.
Ravegnini, Gloria, Margherita Nannini, Valentina Indio, et al.. (2022). miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs. International Journal of Molecular Sciences. 23(20). 12248–12248. 4 indexed citations
11.
Gupta, Anu, et al.. (2021). Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis. Molecular Cancer Therapeutics. 20(7). 1234–1245. 20 indexed citations
12.
Ravegnini, Gloria, César Serrano, Riccardo Ricci, et al.. (2021). miRNA Landscape in Primary Tumors and Matched Metastases in Gastrointestinal Stromal Tumors. Epigenomics. 13(5). 369–377. 2 indexed citations
13.
García-Illescas, David, et al.. (2021). Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Therapeutic Advances in Medical Oncology. 13. 3863601538–3863601538. 34 indexed citations
14.
Jones, Robin L., César Serrano, Margaret von Mehren, et al.. (2021). Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer. 145. 132–142. 85 indexed citations
15.
Bauer, Sebastian, Michael C. Heinrich, Suzanne George, et al.. (2021). Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study. Clinical Cancer Research. 27(23). 6333–6342. 33 indexed citations
16.
Serna, Garazi, Claudia Valverde, Joan Carles, et al.. (2020). Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics. 19(6). 1289–1297. 11 indexed citations
17.
Serrano, César, Alessandro Leal, Yanan Kuang, et al.. (2019). Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clinical Cancer Research. 25(24). 7287–7293. 41 indexed citations
18.
Ravegnini, Gloria, César Serrano, Vittorio Simeon, et al.. (2019). The rs17084733 variant in the KIT 3’ UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics. 14(6). 545–557. 7 indexed citations
19.
Ravegnini, Gloria, Giulia Sammarini, César Serrano, et al.. (2019). Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology. 11. 3862446942–3862446942. 15 indexed citations
20.
Garner, Andrew P., Joseph M. Gozgit, Rana Anjum, et al.. (2014). Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research. 20(22). 5745–5755. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gina Z. D’Amato Breakdown of academic impact, for papers by Daniel A. Rushing Breakdown of academic impact, for papers by Javier Martínez‐Trufero Breakdown of academic impact, for papers by B. Bui Breakdown of academic impact, for papers by J. Buesa Breakdown of academic impact, for papers by Claudia Valverde Breakdown of academic impact, for papers by Rodrigo Ruiz‐Soto Breakdown of academic impact, for papers by Arthur P. Staddon Breakdown of academic impact, for papers by Darrel P. Cohen Breakdown of academic impact, for papers by Agnès Neuville
Rankless by CCL
2026